羊毛硫抗生素乳酸乳球菌素3147野生型及生物工程衍生物的过量生产。
Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147.
作者信息
Cotter Paul D, Draper Lorraine A, Lawton Elaine M, McAuliffe Olivia, Hill Colin, Ross R Paul
机构信息
Department of Microbiology, University College Cork, Cork, Ireland.
出版信息
Appl Environ Microbiol. 2006 Jun;72(6):4492-6. doi: 10.1128/AEM.02543-05.
Abstract
Lacticin 3147 is a broad-spectrum two-peptide lantibiotic whose genetic determinants are located on two divergent operons on the lactococcal plasmid pMRC01. Here we introduce each of 14 subclones, containing different combinations of lacticin 3147 genes, into MG1363 (pMRC01) and determine that a number of them can facilitate overproduction of the lantibiotic. Based on these studies it is apparent that while the provision of additional copies of genes encoding the biosynthetic/production machinery and the regulator LtnR is a requirement for high-level overproduction, the presence of additional copies of the structural genes (i.e., ltnA1A2) is not.
摘要
乳酸链球菌素3147是一种广谱双肽羊毛硫抗生素，其遗传决定簇位于乳球菌质粒pMRC01上的两个不同操纵子上。在此，我们将14个包含不同乳酸链球菌素3147基因组合的亚克隆分别导入MG1363（pMRC01）中，并确定其中一些亚克隆可促进羊毛硫抗生素的过量生产。基于这些研究，很明显，虽然提供编码生物合成/生产机制和调节因子LtnR的基因的额外拷贝是高水平过量生产的必要条件，但结构基因（即ltnA1A2）的额外拷贝的存在并非必要条件。
相似文献
1
Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147.
Appl Environ Microbiol. 2006 Jun;72(6):4492-6. doi: 10.1128/AEM.02543-05.
2
Variable bacteriocin production in the commercial starter Lactococcus lactis DPC4275 is linked to the formation of the cointegrate plasmid pMRC02.
Appl Environ Microbiol. 2004 Jan;70(1):34-42. doi: 10.1128/AEM.70.1.34-42.2004.
3
Exploitation of plasmid pMRC01 to direct transfer of mobilizable plasmids into commercial lactococcal starter strains.
Appl Environ Microbiol. 2001 Jun;67(6):2853-8. doi: 10.1128/AEM.67.6.2853-2858.2001.
4
Regulation of immunity to the two-component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR.
Mol Microbiol. 2001 Feb;39(4):982-93. doi: 10.1046/j.1365-2958.2001.02290.x.
5
Each peptide of the two-component lantibiotic lacticin 3147 requires a separate modification enzyme for activity.
Microbiology (Reading). 2000 Sep;146 ( Pt 9):2147-2154. doi: 10.1099/00221287-146-9-2147.
6
Identification and overexpression of ltnl, a novel gene which confers immunity to the two-component lantibiotic lacticin 3147.
Microbiology (Reading). 2000 Jan;146 ( Pt 1):129-138. doi: 10.1099/00221287-146-1-129.
7
Developing applications for lactococcal bacteriocins.
Antonie Van Leeuwenhoek. 1999 Jul-Nov;76(1-4):337-46.
8
IS1675, a novel lactococcal insertion element, forms a transposon-like structure including the lacticin 481 lantibiotic operon.
J Bacteriol. 2000 Oct;182(19):5600-5. doi: 10.1128/JB.182.19.5600-5605.2000.
9
Elevated enzyme release from lactococcal starter cultures on exposure to the lantibiotic lacticin 481, produced by Lactococcus lactis DPC5552.
J Dairy Sci. 2002 Sep;85(9):2130-40. doi: 10.3168/jds.S0022-0302(02)74291-4.
10
Structure, organization, and expression of the lct gene for lacticin 481, a novel lantibiotic produced by Lactococcus lactis.
J Biol Chem. 1993 Aug 5;268(22):16361-8.
引用本文的文献
1
Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications for infection control.
Gut Microbes. 2025 Dec;17(1):2451081. doi: 10.1080/19490976.2025.2451081. Epub 2025 Jan 16.
2
Incorporation of Non-Canonical Amino Acids into Antimicrobial Peptides: Advances, Challenges, and Perspectives.
Appl Environ Microbiol. 2022 Dec 13;88(23):e0161722. doi: 10.1128/aem.01617-22. Epub 2022 Nov 23.
3
A Cell-Free Platform Based on Nisin Biosynthesis for Discovering Novel Lanthipeptides and Guiding their Overproduction In Vivo.
Adv Sci (Weinh). 2020 Jul 21;7(17):2001616. doi: 10.1002/advs.202001616. eCollection 2020 Sep.
4
Identification and characterisation of capidermicin, a novel bacteriocin produced by Staphylococcus capitis.
PLoS One. 2019 Oct 16;14(10):e0223541. doi: 10.1371/journal.pone.0223541. eCollection 2019.
5
Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.
Probiotics Antimicrob Proteins. 2012 Jun;4(2):108-15. doi: 10.1007/s12602-012-9095-x.
6
The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.
BMC Microbiol. 2013 Sep 26;13:212. doi: 10.1186/1471-2180-13-212.
7
Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.
Microb Biotechnol. 2010 Jul;3(4):473-86. doi: 10.1111/j.1751-7915.2010.00184.x.
8
Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.
Appl Environ Microbiol. 2009 Jul;75(13):4427-34. doi: 10.1128/AEM.00262-09. Epub 2009 May 8.
9
Continuous nisin production with bioengineered Lactococcus lactis strains.
J Ind Microbiol Biotechnol. 2009 Jun;36(6):863-71. doi: 10.1007/s10295-009-0563-6. Epub 2009 Apr 1.
10
Influence of growth conditions on the nisin production of bioengineered Lactococcus lactis strains.
J Ind Microbiol Biotechnol. 2009 Apr;36(4):481-90. doi: 10.1007/s10295-008-0517-4. Epub 2009 Jan 10.
本文引用的文献
1
Identification of the Minimal Replicon of Lactococcus lactis subsp. lactis UC317 Plasmid pCI305.
Appl Environ Microbiol. 1990 Jan;56(1):202-9. doi: 10.1128/aem.56.1.202-209.1990.
2
Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147.
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18584-9. doi: 10.1073/pnas.0509371102. Epub 2005 Dec 8.
3
Bacteriocins: developing innate immunity for food.
Nat Rev Microbiol. 2005 Oct;3(10):777-88. doi: 10.1038/nrmicro1273.
4
Engineering Bacillus subtilis ATCC 6633 for improved production of the lantibiotic subtilin.
Appl Microbiol Biotechnol. 2006 Jan;69(5):532-6. doi: 10.1007/s00253-005-0023-9. Epub 2005 Jul 7.
5
Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations.
Antimicrob Agents Chemother. 2005 Jul;49(7):2606-11. doi: 10.1128/AAC.49.7.2606-2611.2005.
6
Bioactivity quantification of crude bacteriocin solutions.
J Microbiol Methods. 2005 Jul;62(1):121-4. doi: 10.1016/j.mimet.2005.01.006.
7
Enhanced nisin production by increasing genes involved in nisin Z biosynthesis in Lactococcus lactis subsp. lactis A164.
Biotechnol Lett. 2005 Feb;27(3):155-60. doi: 10.1007/s10529-004-7661-3.
8
Biosynthesis and mode of action of lantibiotics.
Chem Rev. 2005 Feb;105(2):633-84. doi: 10.1021/cr030105v.
9
Maturation by LctT is required for biosynthesis of full-length lantibiotic lacticin 481.
Appl Environ Microbiol. 2005 Jan;71(1):562-5. doi: 10.1128/AEM.71.1.562-565.2005.
10
Bacterial lantibiotics: strategies to improve therapeutic potential.
Curr Protein Pept Sci. 2005 Feb;6(1):61-75. doi: 10.2174/1389203053027584.
Zotero 插件